SEC Tracker
Get the app

Eikon Therapeutics EIKN

Eikon Therapeutics presents EIK1001 trial data

Item 7.01 Investor disclosure, Item 8.01 Other events

Form
8-K
Filed
Importance
Notable
  1. 72 participants in TeLuRide-005 trial
  2. 63.1% objective response rate in efficacy-evaluable population
  3. Grade 3 or higher TRAEs in 48.6% of participants
  4. Phase 2/3 trial TeLuRide-008 ongoing with NCT07365319

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Eikon Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Acumen Pharmaceuticals ABOS public float $45M, Jun 30, 2025
  2. Alpha Cognition ACOG public float $149M, Jun 30, 2025
  3. Adaptimmune Therapeutics ADAP
  4. Adma Biologics ADMA public float $4.2B, Jun 30, 2025
  5. Adaptive Biotechnologies ADPT public float $1.4B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.